Illumina IncChange company Symbol lookupSelect an option...ILMN Illumina IncWRLD World Acceptance CorpCWD CaliberCos IncLNTH Lantheus Holdings IncDFIN Donnelley Financial Solutions IncSY So-Young International IncGOTU Gaotu Techedu IncSGDVV Safe & Green Development CorpGLBZ Glen Burnie BancorpPHAR Pharming Group NVGo
Change company Symbol lookup
Select an option...
ILMN Illumina Inc
WRLD World Acceptance Corp
CWD CaliberCos Inc
LNTH Lantheus Holdings Inc
DFIN Donnelley Financial Solutions Inc
SY So-Young International Inc
GOTU Gaotu Techedu Inc
SGDVV Safe & Green Development Corp
GLBZ Glen Burnie Bancorp
PHAR Pharming Group NV
Health Care : Life Sciences Tools & Services | Mid Cap Value
Company profileIllumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.
|
|
|
|
| |
| Latest Earnings Beat Consensus (Q2 ending 06/2023) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q2 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced August 9, 2023 | $0.32 | Q2 Consensus of 14 analysts | $0.02 | Difference from consensus | 1,677.78% | Q3 Earnings will announce | (Unconfirmed) November 1, 2023 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
ILMN's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.